These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 26385641

  • 1. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
    Flowers CR, Brown JR, Rosenthal H, Stock W, Katzen HI, Cohen JB, Sinha R, Lakhanpal S, Leis JF, Waller EK, Jaye DL.
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):694-8. PubMed ID: 26385641
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T, Gercheva-Kyuchukova L, Pylylpenko H, Robak T, Jaksic B, Rekhtman G, Kyrcz-Krzemień S, Vatutin M, Wu J, Sirard C, Hallek M, Engert A.
    Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA.
    Cancer; 2008 Mar 15; 112(6):1288-95. PubMed ID: 18189296
    [Abstract] [Full Text] [Related]

  • 4. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
    Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A.
    J Clin Oncol; 2005 Oct 01; 23(28):7024-31. PubMed ID: 16145065
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 6. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H, German Chronic Lymphocytic Leukemia Study Group.
    J Clin Oncol; 2009 Aug 20; 27(24):3994-4001. PubMed ID: 19597025
    [Abstract] [Full Text] [Related]

  • 7. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
    Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA.
    J Clin Oncol; 2010 Oct 10; 28(29):4500-6. PubMed ID: 20697069
    [Abstract] [Full Text] [Related]

  • 8. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM.
    J Clin Oncol; 2011 Sep 10; 29(26):3559-66. PubMed ID: 21844497
    [Abstract] [Full Text] [Related]

  • 9. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia.
    Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M.
    Leukemia; 2012 Dec 10; 26(12):2549-52. PubMed ID: 22584787
    [No Abstract] [Full Text] [Related]

  • 10. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.
    Montillo M, Tedeschi A, Petrizzi VB, Ricci F, Crugnola M, Spriano M, Spedini P, Ilariucci F, Uziel L, Attolico I, Vismara E, De Blasio A, Zaccaria A, Morra E.
    Blood; 2011 Oct 13; 118(15):4079-85. PubMed ID: 21772050
    [Abstract] [Full Text] [Related]

  • 11. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E.
    J Clin Oncol; 2006 May 20; 24(15):2337-42. PubMed ID: 16618945
    [Abstract] [Full Text] [Related]

  • 12. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
    Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R, Gruppo Italiano Malattie EMatologiche dell’Adulto Working Party for Chronic Lymphoproliferative Disorders.
    Leuk Res; 2014 Feb 20; 38(2):198-203. PubMed ID: 24314589
    [Abstract] [Full Text] [Related]

  • 13. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S, Montillo M, Ribatti D, Mirabelli R, Tedeschi A, Ricci F, Veronese S, Vacca A, Morra E.
    Haematologica; 2007 Oct 20; 92(10):1367-74. PubMed ID: 17768114
    [Abstract] [Full Text] [Related]

  • 14. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA.
    N Engl J Med; 2000 Dec 14; 343(24):1750-7. PubMed ID: 11114313
    [Abstract] [Full Text] [Related]

  • 15. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
    Bezares RF, Stemelin G, Diaz A, Argentieri D, Zubiaur EL, Garay G, Bartomioli M, Ryser R, Milone G.
    Leuk Lymphoma; 2011 Oct 14; 52(10):1936-41. PubMed ID: 21718136
    [Abstract] [Full Text] [Related]

  • 16. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
    Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM.
    Eur J Haematol; 2017 Mar 14; 98(3):254-262. PubMed ID: 27862308
    [Abstract] [Full Text] [Related]

  • 17. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
    Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P.
    J Clin Oncol; 2012 May 10; 30(14):1647-55. PubMed ID: 22493413
    [Abstract] [Full Text] [Related]

  • 18. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.
    J Clin Oncol; 2010 Apr 01; 28(10):1756-65. PubMed ID: 20194844
    [Abstract] [Full Text] [Related]

  • 19. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Gritti G, Reda G, Maura F, Piciocchi A, Baldini L, Molica S, Neri A, Cortelezzi A.
    Leuk Lymphoma; 2012 Mar 01; 53(3):424-9. PubMed ID: 21919823
    [Abstract] [Full Text] [Related]

  • 20. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
    Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG.
    Blood; 2011 Aug 25; 118(8):2085-93. PubMed ID: 21670470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.